ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
20. Juni 2024 13:12 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
23. Mai 2024 17:29 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action
15. Mai 2024 14:43 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Altimmune, Inc. (ALT)
08. Mai 2024 14:02 ET
|
Robbins LLP
Robbins LLP is Investigating the Allegations that Altimmune, Inc. (ALT) Misled Investors Regarding the Viability and Efficacy of its Weight Loss Drug